Loading clinical trials...
Loading clinical trials...
A Randomized, Open-label, 2-period, Parallel Group, Multiple-dose Phase 1 Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930, in Healthy Male Subjects
Conditions
Interventions
D565
D930
Locations
1
South Korea
Seoul National University College of Medicine and Hospital
Seoul, South Korea
Start Date
January 19, 2022
Primary Completion Date
October 18, 2022
Completion Date
November 2, 2022
Last Updated
January 5, 2023
NCT04354545
NCT07298356
NCT07396441
NCT06979752
NCT07390890
NCT07145073
Lead Sponsor
Chong Kun Dang Pharmaceutical
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions